Patent application number | Description | Published |
20080207609 | Pharmaceutical compounds - Fused pyrimidines of formula (I): | 08-28-2008 |
20080207611 | Pharmaceutical compounds - Fused pyrimidines of formula (I): | 08-28-2008 |
20080242665 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R | 10-02-2008 |
20080269210 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R | 10-30-2008 |
20090118275 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 05-07-2009 |
20090156601 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER - The invention provides compounds which are pyrimidines of formula (I): wherein —XR | 06-18-2009 |
20100234370 | PHARMACEUTICAL COMPOUNDS - Fused pyrimidines of formula (I): | 09-16-2010 |
20100280027 | PHARMACEUTICAL COMPOUNDS - Provided herein are methods of treating diseases or disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase, which method includes administering to a patient in need thereof a compound that is a fused pyrimidine of formula (I): | 11-04-2010 |
20120258966 | PHARMACEUTICAL COMPOUNDS - Fused pyrimidines of formula (I): | 10-11-2012 |
20130317017 | PHARMACEUTICAL COMPOUNDS - Fused pyrimidines of formula (I): | 11-28-2013 |
20140294946 | PHARMACEUTICAL COMPOUNDS - Fused pyrimidines of formula (I): | 10-02-2014 |